$12.5 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 119 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 127.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IQV | Buy | IQVIA HLDGS INC | $538,581,000 | +33.5% | 3,796,030 | +1.5% | 4.31% | +24.5% |
| ABBV | Buy | ABBVIE INC | $407,447,000 | +33.7% | 4,150,000 | +3.8% | 3.26% | +24.7% |
| CHTR | Buy | CHARTER COMMUNICATIONS INC Ncl a | $385,088,000 | +22.0% | 755,015 | +4.4% | 3.08% | +13.8% |
| TMUS | New | T-MOBILE US INC | $360,112,000 | – | 3,457,631 | +100.0% | 2.88% | – |
| V | Buy | VISA INC | $347,585,000 | +22.3% | 1,799,373 | +2.0% | 2.78% | +14.1% |
| AON | New | AON PLC | $331,368,000 | – | 1,720,498 | +100.0% | 2.65% | – |
| FB | Buy | FACEBOOK INCcl a | $308,473,000 | +70.1% | 1,358,494 | +24.9% | 2.47% | +58.6% |
| WUBA | New | 58 COM INCspon adr rep a | $267,824,000 | – | 4,965,212 | +100.0% | 2.14% | – |
| EXEL | Buy | EXELIXIS INC | $243,335,000 | +41.3% | 10,250,000 | +2.5% | 1.95% | +31.8% |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $213,150,000 | – | 3,625,000 | +100.0% | 1.71% | – |
| TIF | New | TIFFANY & CO NEW | $186,287,000 | – | 1,527,698 | +100.0% | 1.49% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $179,454,000 | +4.3% | 6,537,500 | +13.7% | 1.44% | -2.8% |
| NYT | New | NEW YORK TIMES COcl a | $173,901,000 | – | 4,137,542 | +100.0% | 1.39% | – |
| BMYRT | Buy | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $158,236,000 | +18.3% | 44,200,000 | +25.6% | 1.27% | +10.3% |
| BX | Buy | BLACKSTONE GROUP INC | $156,853,000 | +754.5% | 2,768,319 | +587.3% | 1.26% | +694.3% |
| WMGI | Buy | WRIGHT MED GROUP N V | $121,852,000 | +86.9% | 4,100,000 | +80.2% | 0.98% | +74.4% |
| FATE | Buy | FATE THERAPEUTICS INC | $120,085,000 | +80.2% | 3,500,000 | +16.7% | 0.96% | +68.0% |
| CZR | New | CAESARS ENTMT CORP | $97,222,000 | – | 8,015,000 | +100.0% | 0.78% | – |
| MYOK | Buy | MYOKARDIA INC | $84,543,000 | +319.4% | 875,000 | +103.5% | 0.68% | +291.3% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $84,179,000 | +145.9% | 525,000 | +50.0% | 0.67% | +129.3% |
| EDU | New | NEW ORIENTAL ED & TECHNOLOGYspon adr | $82,175,000 | – | 631,000 | +100.0% | 0.66% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $74,211,000 | +60.9% | 650,000 | +8.3% | 0.59% | +50.0% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $73,485,000 | +37.2% | 2,250,000 | +12.5% | 0.59% | +27.8% |
| FGEN | Buy | FIBROGEN INC | $65,861,000 | +18.5% | 1,625,000 | +1.6% | 0.53% | +10.5% |
| New | MOMO INCnote 1.250% 7/0 | $64,159,000 | – | 81,601,000 | +100.0% | 0.51% | – | |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $64,090,000 | +57.0% | 575,000 | +1.4% | 0.51% | +46.6% |
| New | IQIYI INCnote 2.000% 4/0 | $61,445,000 | – | 61,438,000 | +100.0% | 0.49% | – | |
| ARNA | New | ARENA PHARMACEUTICALS INC | $56,655,000 | – | 900,000 | +100.0% | 0.45% | – |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $47,596,000 | – | 991,174 | +100.0% | 0.38% | – |
| GBIO | New | GENERATION BIO CO | $44,495,000 | – | 2,118,819 | +100.0% | 0.36% | – |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $44,150,000 | +316.9% | 2,500,000 | +66.7% | 0.35% | +287.9% |
| Buy | THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $40,869,000 | +160.6% | 41,905,000 | +156.1% | 0.33% | +142.2% | |
| LNTH | New | LANTHEUS HLDGS INC | $37,680,000 | – | 2,634,999 | +100.0% | 0.30% | – |
| CYTK | Buy | CYTOKINETICS INC | $35,355,000 | +379.8% | 1,500,000 | +140.0% | 0.28% | +349.2% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $35,343,000 | +82.3% | 850,000 | +25.9% | 0.28% | +70.5% |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $33,187,000 | – | 1,844,757 | +100.0% | 0.27% | – |
| New | IQIYI INCnote 3.750%12/0 | $33,097,000 | – | 29,500,000 | +100.0% | 0.26% | – | |
| Buy | CLOVIS ONCOLOGY INCnote 1.250% 5/0 | $31,197,000 | +1.7% | 51,672,000 | +5.1% | 0.25% | -4.9% | |
| AMRS | New | AMYRIS INC | $29,931,000 | – | 7,009,527 | +100.0% | 0.24% | – |
| New | HORIZON PHARMA INVT LTDnote 2.500% 3/1 | $29,367,000 | – | 15,047,000 | +100.0% | 0.24% | – | |
| TGTX | New | TG THERAPEUTICS INC | $29,220,000 | – | 1,500,000 | +100.0% | 0.23% | – |
| RDUS | Buy | RADIUS HEALTH INC | $28,623,000 | +7.2% | 2,100,000 | +2.2% | 0.23% | 0.0% |
| PLRX | New | PLIANT THERAPEUTICS INC | $27,617,000 | – | 850,801 | +100.0% | 0.22% | – |
| FSCT | Buy | FORESCOUT TECHNOLOGIES INC | $27,666,000 | +0.1% | 1,305,000 | +49.1% | 0.22% | -6.8% |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $25,025,000 | – | 2,500,000 | +100.0% | 0.20% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $24,740,000 | – | 1,000,000 | +100.0% | 0.20% | – |
| FXI | New | ISHARES TRput | $22,331,000 | – | 562,500 | +100.0% | 0.18% | – |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $20,022,000 | – | 20,000,000 | +100.0% | 0.16% | – | |
| HWM | New | HOWMET AEROSPACE INC | $19,007,000 | – | 1,199,186 | +100.0% | 0.15% | – |
| KRYS | Buy | KRYSTAL BIOTECH INC | $18,639,000 | +72.4% | 450,000 | +80.0% | 0.15% | +60.2% |
| LQDA | New | LIQUIDIA TECHNOLOGIES INC | $15,577,000 | – | 1,850,000 | +100.0% | 0.12% | – |
| QURE | Buy | UNIQURE NV | $13,518,000 | +14.0% | 300,000 | +20.0% | 0.11% | +5.9% |
| RPRX | New | ROYALTY PHARMA PLC | $13,351,000 | – | 275,000 | +100.0% | 0.11% | – |
| RC | Buy | READY CAPITAL CORP | $11,733,000 | +28.2% | 1,350,226 | +6.5% | 0.09% | +19.0% |
| CNST | New | CONSTELLATION PHARMCETICLS I | $10,518,000 | – | 350,000 | +100.0% | 0.08% | – |
| ATTO | New | ATENTO S A | $7,712,000 | – | 11,212,205 | +100.0% | 0.06% | – |
| AKUS | New | AKOUOS INC | $5,063,000 | – | 225,000 | +100.0% | 0.04% | – |
| AMTI | New | APPLIED MOLECULAR TRANS INC | $5,028,000 | – | 200,000 | +100.0% | 0.04% | – |
| Buy | INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $4,822,000 | +298.2% | 6,500,000 | +333.3% | 0.04% | +290.0% | |
| ARYBU | New | ARYA SCIENCES ACQUISTION COunit 06/09/2027 | $4,640,000 | – | 400,000 | +100.0% | 0.04% | – |
| RPTX | New | REPARE THERAPEUTICS INC | $4,653,000 | – | 150,000 | +100.0% | 0.04% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC | $4,368,000 | – | 250,000 | +100.0% | 0.04% | – |
| ISEE | New | IVERIC BIO INC | $3,825,000 | – | 750,000 | +100.0% | 0.03% | – |
| Buy | CTRIP COM INTL LTDdbcv 1.990% 7/0 | $3,483,000 | +75.5% | 3,508,000 | +75.4% | 0.03% | +64.7% | |
| RNA | New | AVIDITY BIOSCIENCES INC | $1,413,000 | – | 50,000 | +100.0% | 0.01% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $1,241,000 | – | 148,952 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2024-02-12 |
| SC 13G/A | 2024-02-01 |
| SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.